Medication dosing in patients with chronic kidney disease

Journal of the American Academy of Physician Assistants

Volumn 26, Issue 10, 2013, Pages 19-25

  Zuber, Kim ^a   Liles, Anne Marie ^b   Davis, Jane ^c  

^a PA   (United States)

^b AUBURN UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

antibiotic; antithrombotic; chronic kidney disease; diabetes; medication dosing

Indexed keywords

ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; FIBRINOLYTIC AGENT; NON PRESCRIPTION DRUG;

ARTICLE; CHRONIC KIDNEY FAILURE; HUMAN; PATHOPHYSIOLOGY; PATIENT EDUCATION;

ANALGESICS; ANTI-BACTERIAL AGENTS; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; NONPRESCRIPTION DRUGS; PATIENT EDUCATION AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885185214     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01.JAA.0000435257.26357.a8     Document Type: Article

References (56)

1. U.S. Renal Data System. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.
2. Matzke G, Aronoff GR, Atkinson AJ, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137.
3. US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function- study design, data analysis, and impact on dosing and labeling, May 1998. http://www.fda.gov/downloads/Drugs/ Guidance ComplianceRegulatoryInformation/Guidances/ucm072127.pdf. Accessed February 1, 2013.
4. European Medicines Agency, Committee for Medicinal Products for Human Use. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. 2004. http://www.ema.europa. eu/ docs/en-GB/document-library/Scientifi c-guideline/2009/09/ WC500003123.pdf.
5. Buxton ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill: New York, NY, 2006:1-39.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
7. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modifi cation of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16(3):763-773.
8. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular fi ltration rate from serum creatinine: a new prediction equation. Modifi cation of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
9. Hermsen ED, Maiefski M, Florescu MC, et al. Comparison of the modifi cation of diet in renal disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy. 2009;29:649-655.
10. Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 2009;54:33-42.
11. Wargo KA, Eiland III EH, Hamm W, et al. Comparison of the modifi cation of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments. Ann Pharmacother. 2006;40:1248-1253.
12. Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and modifi cation of diet in renal disease. Pharmacotherapy. 2008;28:1125-1132.
13. Jennings S, de Lemos ML, Levin A, et al. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. J Oncol Pharm Pract. 2010;16:113-119.
14. Spruill WJ, Wade WE, Cobb III HH. Comparison of estimated glomerular fi ltration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother. 2008;6:153-160.
15. National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers, January 2010. http://www.nkdep.nih.gov/ resources/CKD-drug-dosing. shtml. Accessed February 1, 2013.
16. Meijers BK, Bammens B, Verbeke K et al. A review of albumin binding in CKD. Am J Kidney Dis. 2008;51:839-850.
17. Thummel K, Shen D, Isoherranen N, et al. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman J, Limbird L, Goodman G (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill: New York, NY, 2006.
18. Matzke GR, Dowling T. Dosing concepts in renal dysfunction. In: Murphy JE (ed). Clinical Pharmacokinetics Pocket Reference, 5th ed. American Society of Health-System Pharmacists: Bethesda, MD, 2011.
19. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000:26(S4):73-85.
20. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004:17(5):365-370.
21. Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26(10):55-60.
22. Glucophage prescribing information. Princeton, NJ: Bristol-Myers Squibb Co.; 2009.
23. Brazie M. Finding the Sweet Spot: Trouble-shooting Diabetic Dilemmas. Oral presentation, National Kidney Foundation spring clinical meetings, May 11, 2012, Washington, DC. 24. Victoza prescribing information. Princeton, NJ: Novo Nordisk; 2010-2013.
24. Byetta prescribing information. San Diego, CA: Amylin Pharmaceuticals; 2011.
25. Merck Pharmaceuticals prescribing information. April 2012. http://www.merck.com/product/usa/pi-circulars/j/januvia/ januvia-pi.pdf
26. Onglyza prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2012.
27. Tradjenta prescribing information. Ridgefi eld, CT; Boehringer Ingelheim International; 2012.
28. Nesina prescribing information. Deerfi eld, IL: Takeda Pharmaceuticals America, Inc. 2013.
29. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 5th edition. Philadelphia, PA: American College of Physicians, 2007:113.
30. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Medical Clin North Am. 2005;89:649-687.
31. Sulfamethoxazole-trimethoprim. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
32. Nitrofurantoin. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
33. Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India. 2004;52: 632-640.
34. Morphine. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
35. Meperidine. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
36. Neurontin prescribing information. New York, NY: Pfi zer; 2012.
37. Coumadin prescribing. Princeton, NJ: Bristol-Myers Squibb; 2011.
38. Eliquis prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2012.
39. Arixtra prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2011.
40. Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.
41. Heparin sodium. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
42. Lovenox prescribing information. Bridgewater, NJ: Sanofi-Aventis US; 2011.
43. Fragmin prescribing information. New York, NY: Pfi zer; 2010.
44. Argatroban. In: DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
45. Angiomax prescribing information. Parsippany, NJ: The Medicines Co.; 2000.
46. Pradaxa prescribing information. Ridgefi eld, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012.
47. Iprivask prescribing information. Hunt Valley, MD: Canyon Pharmaceuticals Inc.; 2010.
48. Effi ent prescribing information. Indianapolis, IN: Eli Lilly and Co.; 2012.
49. Brilinta prescribing information. Sodertalje, Sweden: AstraZeneca; 2011.
50. Greenberg A (ed). National Kidney Foundation Primer of Kidney Diseases, 5th edition. Elsevier Health Sciences, 2009:446.
51. Matzke GR. Status of hemodialysis drugs in 2002. J Pharm Pract. 2002;15:405-418.
52. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757-773.
53. Paton TW, Cornish WR, Manuel MA, et al. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1985;10:404-425.
54. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3(1 Suppl):1-150.
55. Ehrenpreis ED, Parakkal D, Semer R, Du H. Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration. Colorectal Dis. 2011;13(9):e270-e275.
56. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65-72.